JP2007518818A5 - - Google Patents

Info

Publication number

JP2007518818A5

JP2007518818A5 JP2006551350A JP2006551350A JP2007518818A5 JP 2007518818 A5 JP2007518818 A5 JP 2007518818A5 JP 2006551350 A JP2006551350 A JP 2006551350A JP 2006551350 A JP2006551350 A JP 2006551350A JP 2007518818 A5 JP2007518818 A5 JP 2007518818A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

composition according

peptide

amino acids

minimum

Prior art date

2005-01-21

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 54
• 108090000765 processed proteins & peptides Proteins 0.000 claims 26
• 150000001413 amino acids Chemical class 0.000 claims 15
• 241000124008 Mammalia Species 0.000 claims 11
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 5
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 5
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 5
• 125000000539 amino acid group Chemical group 0.000 claims 5
• 125000003118 aryl group Chemical group 0.000 claims 5
• 230000004792 oxidative damage Effects 0.000 claims 5
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 5
• 230000004770 neurodegeneration Effects 0.000 claims 4
• 208000015122 neurodegenerative disease Diseases 0.000 claims 4
• 210000000056 organ Anatomy 0.000 claims 4
• 206010067125 Liver injury Diseases 0.000 claims 3
• 238000000034 method Methods 0.000 claims 3
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
• 210000004027 cell Anatomy 0.000 claims 2
• 230000000694 effects Effects 0.000 claims 2
• 231100000234 hepatic damage Toxicity 0.000 claims 2
• 208000028867 ischemia Diseases 0.000 claims 2
• 230000008818 liver damage Effects 0.000 claims 2
• 230000010410 reperfusion Effects 0.000 claims 2
• LSNDLIKCFHLFKO-JTQLQIEISA-N (2s)-2-azaniumyl-3-(4-hydroxy-2,6-dimethylphenyl)propanoate Chemical group CC1=CC(O)=CC(C)=C1C[C@H](N)C(O)=O LSNDLIKCFHLFKO-JTQLQIEISA-N 0.000 claims 1
• UEVAHGMTRWGMTB-JBXUNAHCSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 UEVAHGMTRWGMTB-JBXUNAHCSA-N 0.000 claims 1
• SFVLTCAESLKEHH-WKAQUBQDSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide Chemical compound CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N)=O)CC1=CC=CC=C1 SFVLTCAESLKEHH-WKAQUBQDSA-N 0.000 claims 1
• 208000024827 Alzheimer disease Diseases 0.000 claims 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
• 150000008574 D-amino acids Chemical class 0.000 claims 1
• 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 claims 1
• 208000023105 Huntington disease Diseases 0.000 claims 1
• 229940121954 Opioid receptor agonist Drugs 0.000 claims 1
• 208000018737 Parkinson disease Diseases 0.000 claims 1
• 206010040047 Sepsis Diseases 0.000 claims 1
• 208000036142 Viral infection Diseases 0.000 claims 1
• 108010033284 arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide Proteins 0.000 claims 1
• 206010003246 arthritis Diseases 0.000 claims 1
• 210000004899 c-terminal region Anatomy 0.000 claims 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 231100000753 hepatic injury Toxicity 0.000 claims 1
• 208000027866 inflammatory disease Diseases 0.000 claims 1
• 238000007918 intramuscular administration Methods 0.000 claims 1
• 238000007913 intrathecal administration Methods 0.000 claims 1
• 238000001990 intravenous administration Methods 0.000 claims 1
• 238000007914 intraventricular administration Methods 0.000 claims 1
• 239000002756 mu opiate receptor agonist Substances 0.000 claims 1
• 229940126487 mu opioid receptor agonist Drugs 0.000 claims 1
• 201000006417 multiple sclerosis Diseases 0.000 claims 1
• 230000000626 neurodegenerative effect Effects 0.000 claims 1
• 239000003402 opiate agonist Substances 0.000 claims 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1
• 238000007910 systemic administration Methods 0.000 claims 1
• 238000011200 topical administration Methods 0.000 claims 1
• 231100000167 toxic agent Toxicity 0.000 claims 1
• 239000003440 toxic substance Substances 0.000 claims 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
• 108010094098 tyrosyl-arginyl-phenylalanyl-lysinamide Proteins 0.000 claims 1
• 230000009385 viral infection Effects 0.000 claims 1